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Abstract
Background: Pure curcumin has been reported to down-regulate the expression of WT1 in leukemic cells.
However, the molecular mechanism underlying the down-regulation of WT1 by curcumin is not completely
delineated. The purpose of this present study is to identify a new miRNA-mediated mechanism which plays an
important role in the anti-proliferation effects of curcumin in leukemic cells.
Methods: K562 and HL-60 cells were treated with different concentrations of curcumin for 24 and 48 hours, the
level of miR-15a/16-1 and WT1 were detected by qRT-PCR and Western blotting. WT1 expression and cell
proliferation were detected by Western blotting and CCK-8, after curcumin treated-K562 and HL-60 cells were
transfected with anti-miR-15a/16-1 oligonucleotides.
Results: We found that pure curcumin upregulated the expression of miR-15a/16-1 and downregulated the
expression of WT1 in leukemic cells and primary acute myeloid leukemia (AML) cells. Overexpression of miR-15a/
16-1 deduced the protein level of WT1 in leukemic cells, but downregulation of WT1 by siRNA-WT1 could not
increase the expression of miR-15a/16-1 in leukemic cells. These results reveal that curcumin induced-upregulation
of miR-15a/16-1 is an early event upstream to downregulation of WT1. Furthermore, anti-miR-15a/16-1
oligonucleotides (AMO) partly reversed the downregulation of WT1 induced by pure curcumin in leukemic cells
and AMO promoted the growth of curcumin treated-K562 and HL-60 cells.
Conclusion: Thus, these data suggest for the first time that pure curcumin downregulated the expression of WT1
partly by upregulating the expression of miR-15a/16-1 in leukemic cells. miR-15a/16-1 mediated WT1
downregulation plays an important role in the anti-proliferation effect of curcumin in leukemic cells.
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Introduction
The Wilms’ tumor 1 (WT1) gene, which is located at
the short arm of chromosome 11 and contains 10
exons, encodes a DNA-binding transcription factor
essential for embryonal development [1]. High level of
WT1, which is detected in most cases of acute human
leukemia and chronic myelogeous leukemia (CML) in
blast crisis, is associated with a worse long-time
prognosis [2]. Downregulation of WT1 by special siRNA
can inhibit cell proliferation and induce apoptosis in
K562 and HL-60 cells [3]. WT1 acts as a potent tran-
scriptional regulation factor involved in cell growth and
development due to the presence of zinc fingers [4].
WT1 is firstly thought to function as tumor suppressor,
but the following wildly studies support that WT1 acts
as oncogene [5].
Curcumin, a naturally occurring flavinoid and proa-
poptotic compound derived from the rhizome of Cur-
cuma longa, has strong anti-inflammatory, antioxidant,
anticarcinogen, anticancer properties through regulating
multiple downstream cancer-related signaling molecules.
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of NF-kappaB, Jak/STAT, WT1, extracellular signal
regulated kinase and other key molecules involved in
tumorigenesis [6-8]. The mechanisms underlying the
anticancer activity of curcumin have been widely investi-
gated. Bharti et al. showed curcumin decreased NF-kap-
paB in human multiple myeloid cells, leading to the
suppression of proliferation and induction of apoptosis
[7]. Recently more and more data have shown that WT1
is a very important target gene by curcumin [9]. How-
ever the exact mechanism by which curcumin downre-
gulated the expression of WT1 is still not clear.
MicroRNAs (miRNAs) are non-coding regulatory
RNAs of 21 to 25 nucleotides which regulate most of
basal progress such as cell proliferation, survival, apop-
tosis, and differentiation by triggering either transla-
tional repression or mRNA degradation [10].
Furthermore, computational prediction demonstrated
that each miRNA may target hundreds of genes, and
that more than 50% of human protein-coding genes
could be modulated by miRNAs [11]. Recently some
data have indicated pure curcumin inhibited cancer cell
proliferation though miRNAs mediated signal pathway.
Michael et al. showed curcumin inhibited the prolifera-
tion of pancreatic cancer cells through upregulation of
miR-22 and downregulation of miR-199a* [12]. Yang et
al. demonstrated that curcumin induced MCF-7 cells
apoptosis through miR-15a/16-1 mediated down-regula-
tion of Bcl-2 [13]. These emerging results suggest that
specific targeting of miRNAs by natural agents may
open new avenues for the complete elucidation of anti-
tumor activity by curcumin.
In this study, we explored the potential modulation of
miR-15a and miR-16-1 by curcumin in leukemic cells.
Our study aims to explain a new mechanism by which
curcumin downregulates the expression of WT1 via the
upregulation of miR-15a/16-1 in leukemic cells.
Material and methods
Cell lines and primary AML cells
Leukemic cell lines (K562 and HL-60) were employed
for the present study. All cells were cultured in RPMI
1640 supplemented with 10% heat-inactivated fetal
bovine serum (Invitrogen, CA, USA) in humidified 37°C
incubator with 5% CO2. Primary leukemic cells were
obtained from 12 patients with acute myeloid leukemia
( A M L )( 3M 2 ,2M 3 ,3M 4a n d4M 5 ,T h eF i r s t
Affiliated Hospital of Wenzhou Medical College) with
informed consent. The detailed data of the patients were
showed in Table 1. The diagnosis was established
according to French-American-British classification. All
manipulations were approved by the Medical Science
Ethic Committee of Wenzhou Medical College. All
these patients did not receive any chemical therapy
treatments. Primary leukemic cells were isolated by
Ficoll density gradient centrifugation (GE Healthcare,
Uppsala, Sweden). Pure curcumin (Sigma-Aldrich, St
Louis, MO) was dissolved in DMSO as 20 mM stock
solution and kept at -20°C. For experiments, leukemic
cells and primary AML cells were cultured in serial con-
centrations of curcumin and control cultures were trea-
ted with DMSO only.
Plasmids transfection
pRETROSUPER vector expressing miR-15a/16-1 (pRS-
15/16) was constructed as previously described. The
same empty plasmid (pRS-E) was served as negative
control. K562 and HL-60 cells were transiently trans-
fected with 1 μg/mL (final concentration) pRS-15/16 or
pRS-E vector mediated by Lipofectamine™ LTX and
PLUS™ Reagents (Invitrogen) according to the manu-
facturer’s instructions.
RNA extraction
Total RNA from curcumin-treated or untreated leuke-
mic cells were extracted by TRIzol (Invitrogen) Follow-
ing the manufacture’s protocol. RNA concentration and
quality were quantified by measuring the absorbance at
260 nm with Beckman DU6400 spectrophotometer
(Beckman, USA) and gel analysis.
qPCR for miRNA and mRNA expression
Quantitative real-time polymerase chain reaction(qRT-
PCR) analysis for miR-15a and miR-16-1 was performed
in triplicate by the aid of the NCode™ miRNA First-
strand cDNA synthesis (Invitrogen) and SYBR
® Green
PCR Master Mix (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions. U6 snRNA
level was used for normalization. The fold change for
each miRNA in curcumin-treated leukemic cells relative
to untreated cells was calculated using the 2
-ΔΔCT
method [14]. WT1 transcript was determined by
Table 1 The data of acute myeloid leukemia patients
NO Sex Age(y) FAB subtype Chromosome karyotype
1 M 24 M5 46, XY
2 M 36 M3 46, XY PML-RARa+
3 F 47 M5 46, XX
4 F 53 M4 46, XX MYH11-CBFb+
5 M 29 M3 46, XY PML-RARa+
6 F 48 M2 46, XX AML-ETO+
7 F 35 M4 46, XX MYH11-CBFb+
8 M 41 M5 46, XY
9 F 58 M2 46, XX AML-ETO+
10 M 47 M4 46, XY
11 M 41 M2 46, XY
12 F 26 M5 46, XX
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and GAPDH housekeeping genes were used for normali-
zation [15,16]. The following primers were used respec-
t i v e l y ,m i R - 1 5 a :5 ’-TAG CAG CAC ATA ATG GTT
TGT G-3’, miR-16-1: 5’-TAG CAG CAC GTA AAT
ATT GGC G-3’,U 6 :5 ’-CGC AAG GAT GAC ACG
CAA ATT C-3’,W T 1 :s e n s es t r a n d :5 ’-CAG GCT GCA
ATA AGA GAT ATT TTA AG CT-3’, antisense strand:
5’-GAA GTC ACA CTG GTA TGG TTT CTC A-3’,
Taqman probe: 5’- F a m - C T TA C AG A TG C AC A G
CAG GAA GCA CAC TGA-Tamra-3’), ABL: (sense
strand: 5’-GAT GTA GTT GCT TGG GAC CCA-3’,
antisense strand: 5’-TGG AGA TAA CAC TCT AAG
CAT AAC TAA AGG T-3’, Taqman probe: 5’-Fam-
CCA TTT TTG GTT TGG GCT TCA CAC CAT T-
Tamra-3’). GAPDH: (sense strand: 5’-CCA GGT GGT
CTC CTC TGA CTT C-3’, antisense strand: 5’-GTG
GTC GTT GAG GGC AAT G-3’,T a q m a np r o b e :5 ’-
Fam-ACA GCG ACA CCC ACT CCT CCA CCT T-
Tamra-3’).
Cell counting kit-8 (CCK-8) assay
K562 and HL-60 cells were seeded into 96-well plates
(6.0 × 10
3 cells/well). Cell viability was assessed by
CCK-8 assay (Dojin Laboratories, Kumamoto, Japan).
The absorbance at 450 nm (A450) of each well was read
on a spectrophotometer. Three independent experi-
ments were performed in quadruplicate.
Western blotting
Protein extracts from cell lines, patient samples pre-
pared with RIPA lysis buffer (50 mM TrisHCl, 150 mM
NaCl, 0.1% SDS, 1% NP-40, 0.5% sodiumdeoxycholate, 1
mM PMSF, 100 mM leupeptin, and 2 mg/mL aprotinin,
pH 8.0) were separated on an 8% SDS-polyacrylamide
gel and transferred to nitrocellulose membranes. After
blocking with 5% nonfat milk, the membranes were
incubated with an appropriate dilution (WT1 1:2000) of
the primary antibody (Abcom, Cambridge, MA, USA),
followed by incubation with the horseradish peroxidase
(HRP)-conjugated secondary antibody (Abcom). The sig-
nals were detected by chemiluminescence phototope-
HRP kit (Cell Signaling, Danvers, MA, USA). Blots were
stripped and reprobed with anti-GAPDH antibody
(Abcom) as an internal control. All experiments were
repeated three times.
siRNA, mimics, and anti-miR-15a/16-1 oligonucleotide
(AMO) transfection
SiRNA sequences targeting WT1: ccauaccagugugacuuca
corresponds to positions 9-27 of exon 7 within the WT1
coding sequence. SiRNA-WT1 and unspecific control
siRNA (N.C) were synthesized from Invitrogen. 50 nM
SiRNA-WT1 or N.C were transfected into K562 and HL-
60 cells using Hiperfect transfection reagent (Qiagen,
Valencia, USA) according to manufacturer’s instructions.
miR-15a or miR-16-1 mimics was synthesized from Gene
Pharma (Shanghai, China). 40 uM miR-15a or miR-16-1
mimics were transfected into K562 using Hiperfect trans-
fection reagent (Qiagen). The sequences of AMO were
designed according to the principle of sequences comple-
mentary to mature miRNA-15a/16-1. AMO and scram-
ble (SCR) were chemically synthesized by Qiagen. AMO
and SCR (final concentration of 50 nM) were transfected
into K562 and HL-60 cells using the Hiperfect transfec-
tion reagent (Qiagen). All transfections were performed
in triplicate for each time point.
Statistical analysis
T h es i g n i f i c a n c eo ft h ed i f f e r e n c eb e t w e e ng r o u p sw a s
determined by Student’s t-test. A P value of less than .05
was considered statistically significant. All Statistical ana-
lyses were performed with SPSS software (version 13).
Results
Pure curcumin downregulated the expression of WT1 and
effectively inhibited cell proliferation in leukemic cells
As reported previously [17], low concentration of pure
curcumin could inhibit the growth of leukemic cells and
downregulate the expression of WT1. The mRNA and
protein levels of WT1 were detected by qRT-PCR and
Western blotting respectively after K562 and HL-60 cells
were treated with non-cytotoxic doses of pure curcumin
(5, 10, 20 uM for K562 and 2.5, 5, 10 uM for HL-60) [17].
As indicated in Figure 1A-D pure curcumin downregu-
lated the expression of WT1 in time- and concentration
-dependent manner. The mRNA levels of WT1 in the
K562 cells were decreased by 12%, 55%, and 73% in
response to treatment with 5, 10, and 20 μM curcumin at
48 hours compared with the vehicle control (Figure 1A).
To test whether ABL housekeeping gene was regulated
by curcumin, another widely used housekeeping gene
GAPDH was used for normalization. As Additional file 1:
Figure S1A demonstrated no difference occurred in WT1
expression between GAPDH and ABL for normalization.
Meanwhile the protein levels of WT1 in the k562 cells
were significantly decreased after 10 and 20 uM curcu-
min treatment at 48 hours (Figure 1C). In HL-60 cells 5
and 10 uM curcumin also significantly downregulated
the mRNA and protein levels of WT1 (Figure 1B and
1D). Finally CCK-8 assay showed that low concentrations
of pure curcumin could effectively inhibit the growth of
leukemic cells (Figure 1E and 1F).
Pure curcumin upregulated the expression of miR-15a/16-
1 in leukemic cells and primary AML blasts
Although pure curcumin decreased the expression of
WT1 in K562 and HL-60 cells, the exact mechanism is
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expression. Calin et al. reported that miR-15a/16-1
downregulate the protein level of WT1 in MEG-01 cells
[18]. Taking these into consideration we want to explore
whether pure curcumin can regulate the expression of
miR-15a/16-1 in leukemic cells. The levels of miR-15a
and miR-16-1 were detected by qRT-PCR after K562
and HL-60 cells were treated with indicated doses of
pure curcumin. As indicated in Figure 2A-D pure curcu-
min could upregulate the expression of miR-15a/16-1
almost 2-3 folds than untreated groups in time- and
concentration-dependent manner in K562 and HL-60
cells. To test whether the upregulation of miR-15a/16-1
induced by curcumin also occurred in primary leukemic
cells, Primary leukemic cells of 12 AML patients were
separated by Ficoll and were treated with 20 uM pure
curcumin for 48 hours. The upregulation of miR-15a/
16-1 was observed in 10 of 12 patients (Figure 2E and
2F). This data indicate that pure curcumin can upregu-
late the expression of miR-15a and miR-16-1 in leuke-
mic cell lines and primary AML cells. To prove whether
WT1 is downregulated by curcumin in primary AML
cells, WT1 expression is detected by real time RT-PCR
in the same 12 patients. As Additional file 1: Figure S1B
demonstrated the downregulation of WT1 was observed
in 8 of 12 patients. In patients 5 and 10, curcumin upre-
gulated the expression of miR-15a and miR-16-1 but did
not downregulate the expression of WT1.
Overexpression of miR-15a/16-1 could deduce WT1
expression but downregulation of WT1 by siRNA could not
increase the expression of miR-15a/16-1 in leukemic cells
Our previous data showed overexpression of miR-15a/
16-1 obviously reduced the protein level of WT1 after
transfection with pRS-15/16 compared with normal con-
trols in K562 and HL-60 cells, whereas the level of WT1
mRNA was not significantly affected [19]. To prove
whether single miR-15a or miR-16-1 could downregu-
lated the expression of WT1, WT1 protein level was
detected by Western blotting after miR-15a or miR-16-1
mimics were transfected into K562 cells. As demon-
strated in Additional file 1: Figure S1C, both miR-15a
and miR-16-1 could downregulated the expression of
WT1. Although curcumin could upregulate the expres-
sion of miR-15a/16-1 and downregulate the expression
of WT1, whether the upregulation of miR-15a/16-1 was
caused by the downregulation of WT1 is unknown. The
siRNA specific for WT1 was used to mimick the
Figure 1 Pure curcumin down-regulated the expression of WT1 and inhibited the proliferation in K562 and HL-60 cells. (A and C) K562
cell was treated with non-cytotoxic doses of pure curcumin (5, 10, 20 uM) for 24 and 48 hours, then the mRNA level of WT1 was detected by
qRT-PCR and the protein level of WT1 was detected by Western blotting after curcumin treatment for 48 hours. (B and D) HL-60 cell was treated
with non-cytotoxic doses of pure curcumin (2.5, 5, 10 uM) for 24 and 48 hours, then the mRNA level of WT1 was detected by qRT-PCR and the
protein level of WT1 was detected by Western blotting. GAPDH as loading control. (E and F) CCK8 assay was performed when K562 and HL-60
cells were treated for indicated concentration of curcumin for 24, 48 and 72 hours.
# and *represent less than 0.05 and 0.01 of P-values,
respectively, as compared to control.
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protein levels were estimated by quantitative real-time
PCR and Western blotting individually after K562 and
HL-60 cells were transfected with siRNA-WT1 or nega-
tive control for 24 and 48 hours. WT1 siRNA-treated
K562 and HL-60 cells showed a significant reduction of
WT1 mRNA level as compared to control cells (Figure
3A). Furthermore the reduction of mRNA using siRNA
resulted in a markedly decrease of WT1 protein level
after 48 hours in K562 and HL-60 cells (Figure 3B).
Finally we observed that the level of miR-15a and miR-
16-1 were not significantly altered by siRNA-WT1 com-
pared with normal control (Figure 3C and 3D). All these
data demonstrate that downregulation of WT1 can not
affect the expression of miR-15a and miR-16-1 in K562
and HL-60 cell lines. These data strongly indicate that
pure curcumin induced-upregulation of miR-15a/16-1 is
an event upstream to the downregulation of WT1.
Anti-miR-15a/16-1 oligonucleotides (AMO) partly reversed
the down-regulation of WT1 induced by curcumin in
leukemic cells
To further confirm that pure curcumin down-regulated
the expression of WT1 by up-regulation of miR-15a/16-
1, 20 uM curcumin treated-K562 and 10 uM curcumin
treated- HL-60 cells were transfected with 50 nM anti-
miR-15a/16-1 oligonucleotides for 48 hours. The levels
of WT1 protein were detected by Western blotting after
transfection. As Figure 4A and 4B demonstrated that
anti-miR-15a/16-1 oligonucleotides could effectively
decrease the expression of miR-15a and miR-16-1 in
K562 and HL-60 cells. Moreover, anti-miR-15a/16-1 oli-
gonucleotides partly abolished the inhibitory effect of
curcumin on WT1 protein expression (Figure 4C and
4D). Finally, as indicated in Figure 4E and 4F, 20 uM
curcumin treated-K562 and 10 uM curcumin treated-
HL-60 cells were transfected with 50 nM of anti-miR-
15a/16-1 oligonucleotides for 24, 48 and 72 hours, the
CCK-8 assay revealed that anti-miR-15a/16-1 oligonu-
cleotides effectively reversed the inhibition of cell prolif-
eration caused by curcumin in K562 and HL-60 cells.
Discussion
WT1 is considered to play an important role in leuke-
mogenesis because the expression of WT1 increases
1000-10000 fold in primary leukemic cells than normal
cells [20]. Glienke and Bergmann showed that siRNA-
reduced WT1 mRNA expression was associated with a
Figure 2 Pure curcumin upregulated the expression of miR-15a/16-1 in leukemic cell lines and primary AML blasts.( Aa n dC )T h e
expression of miR-15a and miR-16-1 were detected by qRT-PCR after K562 and HL-60 cells were treated with different concentration of
curcumin for 48 hours. (B and D) K562 and HL-60 cells were treated with 20 uM or 10 uM curcumin respectively for 24, 48, and 72 hours, then
the relative expressions of miR-15a and miR-16-1 were detected by qRT-PCR. Data are shown as mean ± SD from three independent
experiments. (E and F) Primary leukemic cells were isolated by Ficoll density gradient centrifugation and were treated with 20 uM pure curcumin
for 48 hours, then the levels of miR-15a and miR-16-1 were detected by qRT-PCR.
# and
&represent less than 0.01 of P-values as compared to
control.
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after transfection for 24 and 48 h [3]. Several studies
indicated that pure curcumin downregulated the expres-
sion of WT1 in leukemic cell lines [9]. Moreover, com-
bined treatment with curcumin and siRNA targeting
WT1 resulted in a significant inhibition of cell prolifera-
tion compared to curcumin-treated cells alone in pan-
creatic cancer cells. All these data suggest that WT1
plays an important role in the anti-proliferative effects
of curcumin. However, the mechanism by which pure
curcumin downregulates WT1 expression is still
unknown. Our data show for the first time that pure
curcumin downregulates WT1 expression via miRNAs
pathway.
The gene expression is regulated via a complicated
network. Semsri et al. reported that pure curcumin
decreased the mRNA and protein levels of WT1
through attenuating WT1 auto-regulatory function and
inhibiting PKCalpha signaling in K562 cells [21]. Our
data showed that curcumin downregulated the expres-
sion of WT1 via miRNAs mediated pathway. However,
whether other regulating factors are involved in the reg-
ulation is still not completely delineated. Therefore it is
difficult to accurately calculated how much of the
down-regulation of WT1 in the curcumin- treated cells
is attributable to the action of the miRNAs. Our pre-
vious data had showed overexpression of miR-15a/16-1
downregulated the protein level of WT1 but not mRNA
level [19]. However, in this report curcumin decreased
the mRNA and protein levels of WT1 in leukemic cells.
Therefore, it is obvious that additional mechanisms [21]
other than the induction of miR-15a/16-1 expression
contribute to curcumin-induced WT1 downregulation.
Taken together, as Additional file 1: Figure S2 indicated
pure curcumin inhibited the cell growth partly through
miR-15a/16-1 mediated downregulation of WT1.
Each miRNA typically targets mRNAs of hundreds of
distinct genes by pairing to the mRNAs of protein-cod-
ing genes. Previous data had reported that Bcl-2 [18],
WT1 [18], caprin-1 [22] and HMGA1 [22] were the tar-
get genes by miR-15a/16-1. WT1 and Bcl-2 are highly
expressed in leukemic cells and function as oncogenes.
The use of SiRNAs against WT1 and Bcl-2 in leukemic
cells could effectively inhibit leukemic cells growth [3].
Overexpression of miR-15a/16-1 in leukemic cells sup-
pressed cell growth probably through targeting WT1
and Bcl-2. However it is difficult to estimate how much
of the inhibition of cell growth in leukemic cells is attri-
butable to the downregulation of WT1 or Bcl-2.
Recent studies have shown that natural agents, includ-
ing curcumin, isoflavone, and EGCG, can regulate the
expression of many miRNAs which increase the sensitiv-
ity of cancer cells to conventional agents and thereby
suppress tumor cell proliferation [23,24]. Zhang et al.
reported that pure curcumin downregulated the expres-
sion of miR-186* in A549/DDP cells. Moreover, overex-
pression of miR-186* significantly inhibited curcumin-
induced apoptosis in A549/DDP cells and transfection
Figure 3 Down-regulation of WT1 by siRNA could not increase the expression of miR-15a/16-1 in leukemic cells. (A and B) K562 and HL-
60 cells were transfected with 50 nM siRNA-WT1, 50 nM N.C or neither of the above for 24 and 48 hours, then the relative mRNA expression of
WT1 and the corresponding WT1 protein were respectively measured by quantitative real-time PCR and Western blotting. GAPDH as loading
control. (C and D) The relative expressions of miR-15a and miR-16-1 were measured by qRT-PCR after K562 and HL-60 cells were transfected with
50 nM siRNA-WT1, 50 nM N.C or neither of the above for 24 and 48 hours. * and
&P < 0.01 versus negative control (N.C).
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apoptosis [25]. Mudduluru et al. demonstrated that in
Rko and HCT116 cells curcumin reduced the expression
of miR-21 in a dose-dependent manner by inhibiting
AP-1 binding to the promoter of miR-21, and induced
the expression of the tumour suppressor programmed
cell death protein 4, which is a target of miR-21 [26].
These data showed curcumin suppress tumor cell
growth through downregulating a panel of onco-miR-
NAs. Saini et al. showed curcumin increased the expres-
sion of miR-203 via inducing the hypomethylation of
the miR-203 promotes. This led to downregulation of
miR-203 target genes Akt2 and Src resulting in
decreased proliferation and increased apoptosis in blad-
der cancer cells [27]. Bao et al. demonstrated that a
novel curcumin analog CDF inhibited pancreatic tumor
growth and aggressiveness through upregulating a panel
of tumor suppressive miRNAs let-7, miR-26a, miR-101
and attenuating EZH2 expression [28]. In a word curcu-
min suppress tumor cell growth through downregulating
a panel of onco-miRNAs or upregulating a panel of
tumor suppressive miRNAs. However, very little data
reported that miRNAs besides miR-15a/16-1 could regu-
late the expression of WT1. More study were required
to prove whether other miRNAs which target WT1
were regulated by curcumin.
Recently it has been reported that curcumin is an epi-
genetic agent. Curcumin inhibits the activity of DNA
methyltransferase I (DNMT1) through covalently block-
ing the catalytic thiolateo fC 1 2 2 6o fD N M T 1 .G l o b a l
Figure 4 Anti-miR-15a/16-1 oligonucleotides (AMO) partly reversed the downregulation of WT1 induced by curcumin in K562 and HL-
60 cells. (A and B) The relative expressions of miR-15a/16-1 were measured by qRT-PCR after K562 and HL-60 cells were transfected with 50 nM
of anti-miR-15a/16-1 oligonucleotides for 48 hours. * and
&P < 0.01 versus negative control (SCR). (C and D) 20 uM curcumin treated-K562 and
10 uM curcumin treated- HL-60 cells were transfected with 50 nM of anti-miR-15a/16-1 oligonucleotides for 48 hours, then the protein levels of
WT1 were measured by Western blotting. GAPDH as loading control. (E and F) 20 uM curcumin treated-K562 and 10 uM curcumin treated- HL-
60 cells were transfected with 50 nM of anti-miR-15a/16-1 oligonucleotides for 24, 48, and 72 hours, then cell proliferation was measured by
CCK-8 assay.
# and
$ represent less than 0.05 of p-values, compared respectively with pure curcumin treatment alone at the same time.
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mately 20% in a leukemic cell line which is treated with
30 uM curcumin compared with untreated basal methy-
lation levels [29]. Curcumin can also modulates histone
acetyltransferases (HAT) and histone deacetylases
(HDACs) [30]. Previous data had indicated that curcu-
min upregulated the levels of miR-15a and miR-16-1 in
MCF-7 and other cells [13]. Since curcumin is a DNA
hypomethylation agent, epigenetic modulation of micro-
RNA expression may be an important mechanism
underlying biological effects of curcumin. Curcumin
probably regulates the expression of miR-15a/16-1
through epigenetic modulation.
Overexpression of miR-15a and 16-1 downregulated
the expression of WT1. Calin et al. showed that WT1
was a target gene of miR-15a/16-1 in MEG-01 cells by
microarray and proteomics analysis [18]. However,
whether WT1 was directly targeted by miR-15a and
miR-16-1 in leukemic cells was not verified in lab. Our
previous data showed that overexpression of miR-15a
a n dm i R - 1 6 - 1i nK 5 6 2a n dH L - 6 0c e l l ss i g n i f i c a n t l y
downregulated the protein level of WT1. However the
mechanism of miR-15a/16-1 downregulating WT1 pro-
tein level is not through targeting mRNAs according to
the degree of complementarity with their 3’untranlation
region. In conclusion, miR-15a and miR-16-1 probably
regulated WT1 expression through an indirect effect on
WT1 [19].
Anti-miR-15a/16-1 has the ability to efficiently and
specifically silence endogenous miR-15a and miR-16-1.
Our data showed anti-miR-15a/16-1 could partly reverse
the expression of WT1 in curcumin-treated K562 and
HL-60 cells. These results suggest that the decrease of
WT1 expression is partly attributable to the increased
expression of miR-15a and miR-16-1 in curcumin-treated
leukemic cells. Thus our data suggest that one of the
important anti-proliferatione f f e c t so fc u r c u m i no nl e u -
kemic cells is via miRNAs pathway. Given that many
miRNAs are regulated by pure curcumin, many further
experiments will be required to define other miRNAs
besides miR-15a/16-1 are regulated by curcumin and
play an important role in anti-tumor effects of curcumin.
Conclusion
Therefore, we conclude that pure curcumin can
decrease WT1 expression partly through upregulating
the expression of miR-15a and miR-16-1. Our data
show for the first time that miRNAs pathway plays an
important role in the function of anti-proliferation by
pure curcumin in leukemic cells.
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Additional material
Additional file 1: Figure S1. (A) K562 cells were treated with 5, 10, 20
uM pure curcumin for 48 hours, then the mRNA level of WT1 was
detected by qRT-PCR. ABL and GAPDH served as different housekeeping
for normalization. (B) Primary leukemic cells of 12 AML patients were
separated by Ficoll and were treated with 20 uM pure curcumin for 48
hours, then the mRNA levels of WT1 were detected by qRT-PCR. (C) The
protein level of WT1 was detected by Western blotting after negative
control(N.C), miR-15a and miR-16-1 mimics were transfected into K562
for 48 hours. Figure S2. An illustration of the potential mechanisms of
curcumin action in leukemic cells. Curcumin upregulated the expression
of miR-15a/16-1 in leukemic cells. Overexpression of miR-15a/16-1
obviously reduced the protein level of WT1. However, downregulation of
WT1 by siRNA could not increase the expression of miR-15a/16-1. These
events showed that curcumin induced-upregulation of miR-15a/16-1 was
an event upstream to the downregulation of WT1. Finally anti-miR-15a/
16-1 oligonucleotides (AMO) partly reversed the down-regulation of WT1
induced by curcumin in leukemic cells and reversed the inhibition of cell
proliferation caused by curcumin in K562 and HL-60 cells.
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